Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711671 · ClinicalTrials.gov registry record · Phase 1
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01711671 is a Phase 1 study that has completed, run by Leap Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT01711671, a Phase 1 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
Interventions
- DRUG Standard of Care
- DRUG DKN-01 300 mg
- DRUG DKN-01 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711671
The ClinicalTrials.gov registry entry for NCT01711671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leap Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT01711671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711671 about?
NCT01711671 is a clinical study titled "A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
What is the current status of trial NCT01711671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01711671?
The interventions under investigation include: Standard of Care (DRUG), DKN-01 300 mg (DRUG), DKN-01 600 mg (DRUG).
Who is sponsoring clinical trial NCT01711671?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.